Received Mar 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Late 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 49-year-old female patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 16th May 2024). On 04-MAR-2025, the patient received the 2nd dose of Twinrix. On 04-MAR-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late 2nd dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:04-MAR-2025 Pharmacist called to verify when the 3rd dose of Twinrix could be administered. The reporter did not consent to follow-up. No lot number nor expiry date were available. The patient received 2nd dose of Twinrix later than the recommended schedule, which led to lengthening of vaccination schedule.